Entering text into the input field will update the search result below

Roche's Lunsumio gets FDA priority review for blood cancer subtype

Jul. 06, 2022 4:30 AM ETRoche Holding AG (RHHBY), RHHBFBy: Ravikash, SA News Editor

Sunset view of riverside of Rhine dominated by the Roche tower in Switzerland

trabantos/iStock via Getty Images

  • The U.S. Food and Drug Administration (FDA) granted priority review to Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) immunotherapy Lunsumio to treat adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.